Whale Large Capital
  • Politics
  • World News
  • Business
  • Investing
  • Politics
  • World News
  • Business
  • Investing

Whale Large Capital

Politics

Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

by November 26, 2024
November 26, 2024
Ozempic, Wegovy covered by Medicare and Medicaid under Biden admin proposal for anti-obesity GLP-1 drugs

The Biden administration is expanding coverage of anti-obesity drugs such as Ozempic and Wegovy for people with Medicare and Medicaid through a new proposal from the Department of Health and Human Services, a White House official says. 

Medicare currently only covers these drugs for people who are diagnosed with diabetes or cardiovascular disease with obesity, or for people who are overweight, according to the official, who added that while some state Medicaid programs cover the GLP-1 medications for obesity, many do not. 

The new HHS proposal, they said, would require both Medicare and Medicaid to cover the drugs for people with obesity as a treatment for the condition.

‘Today’s new proposal would expand access to these innovative medications for obesity, which is widely recognized as a disease and help an estimated 3.4 million Americans with Medicare. Medicare coverage would reduce out-of-pocket costs for these prescription drugs by as much as 95 percent for some enrollees,’ the White House said in a statement Tuesday. 

‘Approximately 4 million adult Medicaid enrollees would also gain new access to these medications. This proposal would allow Americans and their doctors to determine the best path forward so they can lead healthier lives, without worrying about their ability to cover these drugs out-of-pocket, and ultimately reduce health care costs to our nation,’ the statement added. 

The White House says that ‘for too many Americans, these critical treatments are too expensive and therefore out of reach,’ and, ‘without insurance coverage, these drugs can cost someone as much as $1,000 a month.’

GLP-1 (glucagon-like peptide) receptor agonists are commonly prescribed to patients with type 2 diabetes (to stabilize blood glucose levels) or obesity (to assist with weight loss). 

‘These medications slow down digestion, which means food stays in the stomach longer,’ said Dr. Alfred Bonati, the founder of the Bonati Spine Institute in Florida, previously told Fox News Digital. 

The White House says an estimated 42 million Americans today have obesity, ‘with increased risk of all-cause mortality and multiple related comorbidities such as diabetes, cardiovascular disease, stroke, some cancers, and more.’ 

‘Over the past few years, there have been major scientific advancements in the treatment of obesity, with the introduction of new life-saving drugs. These anti-obesity medications can help prevent the development of Type 2 diabetes. Furthermore, these drugs reduce deaths and sickness from heart attack and other cardiovascular outcomes by up to 20%,’ the White House added. 

Fox News’ Melissa Rudy contributed to this report. 

This post appeared first on FOX NEWS
0
FacebookTwitterGoogle +Pinterest
previous post
Putin’s ‘Fog of War’ missile confuses experts, but that’s his plan
next post
Stop funding the woke and the stupid

You may also like

Obama’s presence and Trump’s policies consume 11th-hour rally...

November 2, 2025

GOP senators push Kamala Harris testimony as House...

August 23, 2025

Democrats coordinate multi-state response to Trump’s funding freeze

January 29, 2025

IAEA chief calls Israeli president, reportedly says Iran...

June 13, 2025

Blame game intensifies in Congress as government shutdown...

March 1, 2025

Donald Trump Jr. has ‘ZERO interest’ in a...

May 21, 2025

‘Safer, stronger, and freer’: Securing the border set...

January 17, 2025

Ric Grenell under consideration to be Trump’s point...

November 23, 2024

‘Not committed’: Conservatives warn Mike Johnson still has...

November 15, 2024

Trump picks Scott Turner as secretary for Department...

November 23, 2024

    Subscribe today to receive exclusive access to all our retirement secrets and income strategies, including special financial news and updates from our experts. From time to time, our newsletters feature valuable insights and analysis on the latest financial trends. Don't miss out on these exclusive updates – join our subscription to stay informed!


    By opting in you agree to receive emails from us. Your information is secure and your privacy is protected.



    Latest

    • Iran nuclear talks ‘didn’t pass the smell test’ before Trump launched strikes, says Vance

      March 3, 2026
    • Iranian drone strikes shut down Qatar LNG production facilities, as energy prices surge

      March 3, 2026
    • Trump sends official notification to Congress on strikes against Iran

      March 3, 2026
    • Musk, xAI tout newest Grok update as only ‘non-woke’ platform: ‘Doesn’t equivocate”

      March 3, 2026
    • Trump admin warned lawmakers Israel was ‘determined to act with or without us’ before massive Iran strikes

      March 3, 2026
    • Iran starts ‘indiscriminate’ strikes across Gulf of Oman, hits shadow tanker tied to regime

      March 3, 2026

    Categories

    • Business (853)
    • Investing (661)
    • Politics (7,757)
    • World News (3,213)

    Disclaimer: WhaleLargeCapital.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2026 whalelargecapital.com | All Rights Reserved